FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2468193723> ?p ?o ?g. }

• W2468193723 endingPage "ii45" @default.
• W2468193723 startingPage "ii45" @default.
• W2468193723 abstract "Introduction: Regorafenib, a potent multikinase inhibitor, is currently approved for the treatment in pretreated patients with metastatic colorectal cancer The CORECT registry is a non-interventional post-marketing database, gathering information about patients with colorectal cancer and treated with targeted agents Methods: A total of 150 patients treated with regorafenib in clinical practice, between 2011 and 2015, were identified. Results: The majority of patients were male (n = 93, 62.8 %) and median age at diagnosis was 60.1 years. The primary tumour location was the colon mostly (n = 83, 56.1%), the rectum primary was reported in 43.9% of cases. The majority of patients (n = 95, 64.2%) presented with distant metastases at diagnosis. K-RAS was found mutated in 61 patients (41.2%) and N-RAS in 20 patients (13.5%). Most patients underwent prior surgery (n = 129, 89.0%). Radiotherapy for primary tumour was reported in 33 patients (15.6%). Prior adjuvant chemotherapy was administered in 47 patients (32.2. At regorafenib initiation, almost all patients (97.1%) were fully active or slightly restricted in physical activity (PS 0-1). The metastatic sites at regorafenib initiation were mostly localised in the liver (n = 98, 72.6%), other metastasis sites included lungs, lymphatic nodes and peritoneum. The majority of patients 60.1% were treated with regorafenib in third line, 24.3% in fourth line, 8.1% in fifth line, 7,4% in second line of palliative setting. Prior targeted therapies were bevacizumab (n = 137, 92.6%), cetuximab (n = 38, 25.7%) and panitumumab (n = 33, 22.3%). Median progression-free survival (PFS) was 3.5 months (95% CI 2.7- 4.2) and median overall survival (OS) was 10.1 months (95% CI 5.8-14.4). One year after regorafenib initiation, the survival rate was 45.7% (95% CI 33.6-57.7). There were no complete responses; partial response was observed in three patients, and 45 patients showed stable disease in a group of patients with completed regorafenib. Serious adverse events occurred in two patients (1.4%). The main reported adverse events were skin toxicity (grade 2 in 4.1%), fatigue (1.4%), hypertension (0.7%). One patient died during the treatment with regorafenib (death related to the treatment). Conclusion: Results from our registry support the use of regorafenib as a standard of care in patients with advanced colorectal cancer, considering its acceptable safety profile and clinical efficacy." @default.
• W2468193723 created "2016-07-22" @default.
• W2468193723 creator A5000705184 @default.
• W2468193723 creator A5002161879 @default.
• W2468193723 creator A5009523282 @default.
• W2468193723 creator A5014987293 @default.
• W2468193723 creator A5015100866 @default.
• W2468193723 creator A5020077097 @default.
• W2468193723 creator A5037779314 @default.
• W2468193723 creator A5056372015 @default.
• W2468193723 creator A5076974443 @default.
• W2468193723 creator A5087639149 @default.
• W2468193723 date "2016-06-01" @default.
• W2468193723 modified "2023-10-17" @default.
• W2468193723 title "P-153 Regorafenib in the real-life clinical practice: data from the czech registry" @default.
• W2468193723 doi "https://doi.org/10.1093/annonc/mdw199.147" @default.
• W2468193723 hasPublicationYear "2016" @default.
• W2468193723 type Work @default.
• W2468193723 sameAs 2468193723 @default.
• W2468193723 citedByCount "1" @default.
• W2468193723 countsByYear W24681937232017 @default.
• W2468193723 crossrefType "journal-article" @default.
• W2468193723 hasAuthorship W2468193723A5000705184 @default.
• W2468193723 hasAuthorship W2468193723A5002161879 @default.
• W2468193723 hasAuthorship W2468193723A5009523282 @default.
• W2468193723 hasAuthorship W2468193723A5014987293 @default.
• W2468193723 hasAuthorship W2468193723A5015100866 @default.
• W2468193723 hasAuthorship W2468193723A5020077097 @default.
• W2468193723 hasAuthorship W2468193723A5037779314 @default.
• W2468193723 hasAuthorship W2468193723A5056372015 @default.
• W2468193723 hasAuthorship W2468193723A5076974443 @default.
• W2468193723 hasAuthorship W2468193723A5087639149 @default.
• W2468193723 hasBestOaLocation W24681937231 @default.
• W2468193723 hasConcept C121608353 @default.
• W2468193723 hasConcept C126322002 @default.
• W2468193723 hasConcept C141071460 @default.
• W2468193723 hasConcept C143998085 @default.
• W2468193723 hasConcept C2776248978 @default.
• W2468193723 hasConcept C2776694085 @default.
• W2468193723 hasConcept C2777802072 @default.
• W2468193723 hasConcept C2778332735 @default.
• W2468193723 hasConcept C2779013556 @default.
• W2468193723 hasConcept C2779998722 @default.
• W2468193723 hasConcept C2781074409 @default.
• W2468193723 hasConcept C526805850 @default.
• W2468193723 hasConcept C71924100 @default.
• W2468193723 hasConcept C90924648 @default.
• W2468193723 hasConceptScore W2468193723C121608353 @default.
• W2468193723 hasConceptScore W2468193723C126322002 @default.
• W2468193723 hasConceptScore W2468193723C141071460 @default.
• W2468193723 hasConceptScore W2468193723C143998085 @default.
• W2468193723 hasConceptScore W2468193723C2776248978 @default.
• W2468193723 hasConceptScore W2468193723C2776694085 @default.
• W2468193723 hasConceptScore W2468193723C2777802072 @default.
• W2468193723 hasConceptScore W2468193723C2778332735 @default.
• W2468193723 hasConceptScore W2468193723C2779013556 @default.
• W2468193723 hasConceptScore W2468193723C2779998722 @default.
• W2468193723 hasConceptScore W2468193723C2781074409 @default.
• W2468193723 hasConceptScore W2468193723C526805850 @default.
• W2468193723 hasConceptScore W2468193723C71924100 @default.
• W2468193723 hasConceptScore W2468193723C90924648 @default.
• W2468193723 hasLocation W24681937231 @default.
• W2468193723 hasLocation W24681937232 @default.
• W2468193723 hasLocation W24681937233 @default.
• W2468193723 hasOpenAccess W2468193723 @default.
• W2468193723 hasPrimaryLocation W24681937231 @default.
• W2468193723 hasRelatedWork W1792988773 @default.
• W2468193723 hasRelatedWork W2075960712 @default.
• W2468193723 hasRelatedWork W2139792997 @default.
• W2468193723 hasRelatedWork W2566782051 @default.
• W2468193723 hasRelatedWork W2617055067 @default.
• W2468193723 hasRelatedWork W2768563229 @default.
• W2468193723 hasRelatedWork W2984534749 @default.
• W2468193723 hasRelatedWork W3030758306 @default.
• W2468193723 hasRelatedWork W349909140 @default.
• W2468193723 hasRelatedWork W861557199 @default.
• W2468193723 hasVolume "27" @default.
• W2468193723 isParatext "false" @default.
• W2468193723 isRetracted "false" @default.
• W2468193723 magId "2468193723" @default.
• W2468193723 workType "article" @default.